Remdesivir, hydroxychloroquine, lopinavir and interferon have almost no effect on patient mortality in the treatment of coronavirus, the Financial Times reported, citing a study by the World Health Organization (WHO).
These drugs do not reduce the risk of death with Covid-19 and do not reduce the number of patients in need of intensive care.
Data from the treatment of 11,266 hospitalized patients were used in the study.
Four of the most promising treatment regimens for Covid-19 have been tested in an international multicenter clinical trial of the World Health Organization SOLIDARITY. Among them is treatment with the drug remdesivir, which the Russian Ministry of Health will include in clinical practice and recommendations for the treatment of the infection.
Since the beginning of the pandemic, nearly 38.4 million cases of Covid-19 have been identified worldwide, and more than 1.5 million patients have died, according to the WHO. The situation is most difficult in the United States, India and Brazil.
At the same time, researchers at the University of Hong Kong have found that an affordable antimicrobial used to treat stomach ulcers and bacterial infections is effective in fighting Covid-19.
It is ranitidine bismuth citrate (RBC), which has been tested on hamsters.
As a result of the experiment, the viral load in the lung cells of infected rodents has decreased more than 1000 times, informs MedicalXpress. In addition, the drug significantly reduced the level of major anti-inflammatory cytokines and chemokines in the event of a severe course of Covid-19.
The researchers noted that RBC had low cytotoxicity with a high selectivity index, suggesting its safety compared with remdesivir.